Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc operates with a negative equity position of -$292.93 million and a total liabilities of $401.34 million, indicating a levered capital structure with a debt-to-equity ratio of -1.02. The company's liquidity position is characterized by $60.54 million in cash and equivalents, but with $299.23 million in long-term debt, the net cash position is negative. The current ratio of 1.12 suggests the company has sufficient current assets to cover its current liabilities, but the overall liquidity risk is assessed as medium. Profitability metrics show a mixed picture. The company reported a gross profit of $140.12 million, but this was offset by an operating loss of $153.07 million and a net loss of $196.04 million. Return on equity is positive at 6.69%, but return on assets is negative at -1.81%, indicating that the company is not generating returns that cover its cost of capital. These figures are below the industry median for profitability, suggesting underperformance relative to peers. Geographically and segment-wise, Karyopharm's revenue concentration is not disclosed in the available data. However, the company's operations are primarily focused on the development and commercialization of oncology therapeutics, with no material diversification into other therapeutic areas or geographic regions. The company's growth trajectory is uncertain. Revenue for the latest period was $146.07 million, but there is no disclosed revenue growth rate or outlook for the next fiscal year. Analysts have provided a wide range of price targets, from $7.00 to $16.00, with a mean of $13.40 and a median of $15.00, indicating a lack of consensus on the company's future performance. Risk factors include a high level of debt relative to equity and a negative net cash position, which could constrain the company's ability to fund operations or invest in growth opportunities. The risk assessment indicates a low probability of dilution, but the company's negative equity and operating cash flow of -$75.37 million raise concerns about its ability to service debt and maintain operations without additional financing. Recent events include the publication of the latest financial data and analyst estimates. No recent filings or transcripts are available in the provided data to indicate significant corporate developments or strategic shifts.